BUBBLE trial

Chief investigator - Professor Kwee Yong, University College London
Cancer type - Myeloma
A phase Ib study of BKM120 with bortezomib in defined genetic subgroups of patients with relapsed or refractory multiple myeloma
Award start date: 17 Mar 2014
Recruitment start date: 23 Jun 2016
Award duration: 6 years (72 months)

This study is looking at treatment for people with certain gene changes (mutations) in their myeloma cells. It is for people whose myeloma has come back or treatment has stopped working. 

People with gene mutations in their myeloma cells may cause them to not respond to usual chemotherapy as well as other treatments.

Bortezomib is one of the usual therapies for myeloma, and researchers think that adding another drug called buparlisib (also known as BKM120) could help people with gene changes.

Bortezomib is a proteasome inhibitor. It works by blocking the action of proteasomes which help the cell break down proteins that are not needed. This causes proteins to build up inside the cell causing the cell to stop growing and die.

Buparlisib is a PI3K inhibitor, and inhibits the PI3K cell signalling pathway which is often overactivated in cancer allowing cancer cells to grow rapidly.

The aims of the study are to:

  • Find the highest safe dose of buparlisib combined with bortezomib
  • Test the best combination dose in people with the gene changes
  • Learn more about the side effects

This trial is now closed to recruitment, and we hope to report the results soon.